Success Metrics

Clinical Success Rate
100.0%

Based on 2 completed trials

Completion Rate
100%(2/2)
Active Trials
3(60%)
Results Posted
50%(1 trials)

Phase Distribution

Ph phase_3
1
20%
Ph early_phase_1
1
20%
Ph not_applicable
1
20%
Ph phase_2
2
40%

Phase Distribution

1

Early Stage

2

Mid Stage

1

Late Stage

Phase Distribution5 total trials
Early Phase 1First-in-human
1(20.0%)
Phase 2Efficacy & side effects
2(40.0%)
Phase 3Large-scale testing
1(20.0%)
N/ANon-phased studies
1(20.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

2 of 2 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

3

trials recruiting

Total Trials

5

all time

Status Distribution
Active(3)
Completed(2)

Detailed Status

Completed2
Recruiting2
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
5
Active
3
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Early Phase 11 (20.0%)
Phase 22 (40.0%)
Phase 31 (20.0%)
N/A1 (20.0%)

Trials by Status

active_not_recruiting120%
completed240%
recruiting240%

Recent Activity

3 active trials
Showing 5 of 5
recruitingnot_applicable

New Methods for Evaluating Preventive Migraine Treatment

NCT07071506
recruitingphase_2

Belimumab and Rituximab Combination Therapy for the Treatment of Diffuse Cutaneous Systemic Sclerosis

NCT03844061
completedphase_2

Study of Efficacy, Safety, Tolerability and Pharmacokinetics of MIJ821 in Participants With Treatment- Resistant Depression (TRD)

NCT05454410
completedearly_phase_1

Effect of Novel Glucagon Receptor Antagonist REMD-477 on Glucose and Adipocyte Metabolism in T2DM

NCT05093517
active_not_recruitingphase_3

Study of the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of BCD-180 in Patients With Axial Spondyloarthritis (LEVENTA)

NCT06333210

Clinical Trials (5)

Showing 5 of 5 trials
NCT07071506Not Applicable

New Methods for Evaluating Preventive Migraine Treatment

Recruiting
NCT03844061Phase 2

Belimumab and Rituximab Combination Therapy for the Treatment of Diffuse Cutaneous Systemic Sclerosis

Recruiting
NCT05454410Phase 2

Study of Efficacy, Safety, Tolerability and Pharmacokinetics of MIJ821 in Participants With Treatment- Resistant Depression (TRD)

Completed
NCT05093517Early Phase 1

Effect of Novel Glucagon Receptor Antagonist REMD-477 on Glucose and Adipocyte Metabolism in T2DM

Completed
NCT06333210Phase 3

Study of the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of BCD-180 in Patients With Axial Spondyloarthritis (LEVENTA)

Active Not Recruiting

All 5 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
5